BioNTech Flashes Dual Late-Stage Momentum at ASCO as Oncology Pipeline Nears First Filing

BioNTech presents strong Pumitamig lung cancer data and advances pivotal ADC for endometrial cancer, targeting first US regulatory submission.

The German biotech used the American Society of Clinical Oncology meeting to showcase not one but two late-stage programs, each representing a different leg of its post-Covid transformation. While investors have been parsing the early efficacy signals from Pumitamig in lung cancer, the company also quietly advanced a pivotal ADC study in endometrial cancer that could yield the first US regulatory submission in its history.

On the lung cancer front, BioNTech and Bristol Myers Squibb unveiled interim data on 30 May from the global ROSETTA Lung-02 trial. The combination of Pumitamig — a bispecific antibody targeting PD-L1 and VEGF-A — plus chemotherapy produced a confirmed objective response rate of 57.1% in non-squamous non-small cell lung cancer and 68.4% in squamous disease, with a disease control rate hitting 100%. Among patients with a PD-L1 TPS of 50% or higher, the confirmed response rate climbed to 100%. The median follow-up stood at 9.0 months across 40 evaluable patients.

The safety profile drew particular attention. BioNTech and its partner described manageable toxicity and a low discontinuation rate, a relevant factor as the bispecific faces stiff competition from Summit’s and Akeso’s Ivonescimab, which has already produced pivotal data in China and is awaiting US results from the Harmoni-3 study later this year.

Pumitamig is now underpinned by three global Phase 3 trials in NSCLC. Alongside ROSETTA Lung-02, the ROSETTA Lung-201 study compares it to Durvalumab following chemoradiotherapy in stage III disease, while ROSETTA Lung-202 pits it against Pembrolizumab in the first-line PD-L1-high setting. The breadth of the program signals that BioNTech intends Pumitamig to compete across stages and patient segments, not merely in a niche.

Parallel to the bispecific push, BioNTech presented a poster on 1 June for Fern-EC-01, a Phase 3 study of the antibody-drug conjugate Trastuzumab Pamirtecan (BNT323 / DB-1303) in recurrent HER2-expressing endometrial cancer. The open-label, randomized, multi-site trial plans to enrol 480 patients from June 2025 through March 2028, with a comparator arm of investigator’s choice chemotherapy in patients who have already received platinum-based therapy and an immune checkpoint inhibitor. The primary endpoints differ by cohort: progression-free survival in cohort one, objective response rate in cohort two.

Though the ASCO poster is a “trial-in-progress” presentation — offering no efficacy data yet — it carries unusual weight because BioNTech disclosed in the first quarter that the potentially registration-relevant cohort had finished enrolment. The company and its partner DualityBio intend to file a Biologics License Application later this year, pending regulatory feedback. That makes Fern-EC-01 a more tangible near-term catalyst than the typical early-stage poster.

Finances Underpin the Transition

BioNTech’s balance sheet remains formidable even as revenue shrinks. First-quarter 2026 sales came in at €118.1 million, down from €182.8 million a year earlier, as Covid vaccine revenue continued to fade. The net loss widened to €531.9 million from €415.8 million, driven by research spending of €557.0 million flowing into immuno-oncology and ADC programmes. Against that stands a liquidity position of €16.76 billion, giving the group ample runway.

The cost side is being addressed head-on. BioNTech has initiated a restructuring that will see it exit sites in Idar-Oberstein, Marburg, Singapore and former CureVac locations, with up to 1,860 jobs affected. Annual savings are expected to reach roughly €500 million by 2029, with freed-up capital channelled into oncology development. The board has also authorised a $1.0 billion share buyback programme over twelve months, a signal of confidence that the pipeline can eventually restore profitability.

Analyst Confidence Graded at Last

UBS upgraded BioNTech to Buy from Neutral and raised its price target to $135 from $117, driven largely by the Pumitamig data. Analyst David Dai described the bispecific as a credible candidate for a leading position in its class. The bank forecasts 2026 revenue of €2.10 billion — in line with BioNTech’s own guidance of €2.0–2.3 billion — and projects €4.44 billion in sales by 2030, with a return to net income of €398 million that year.

The market, however, remained unmoved. BioNTech’s shares traded at €78.90 in the primary article and at €78.80 in the secondary piece, down 4.31% on the respective day. The stock sits roughly 22% below its 52-week high of €101.90 and has shed over a fifth of its value in twelve months.

What Comes Next

BioNTech now runs more than 25 clinical trials in mid-to-late stages, with 13 programmes considered registration-relevant. The immediate inflection points are the BLA filing for Trastuzumab Pamirtecan later this year and the maturation of ROSETTA Lung-02’s late-stage data. For a company whose revenue base has shrunk dramatically since the vaccine bonanza, the depth of the pipeline — spanning Pumitamig, multiple ADCs targeting HER2, HER3 and B7H3, and a Phase 2 readout in platinum-resistant ovarian cancer from Gotistobart plus Pembrolizumab — will determine whether the ASCO narrative translates into a sustainable equity story.